Vanguard Asset Management’s Castle Biosciences CSTL Stock Holding History
Bought
Maintained
Sold
Other funds holding CSTL
Vanguard Asset Management's CSTL Position: Q3 2026 in Review
Vanguard Asset Management increased its Castle Biosciences (CSTL) stake by 26% in Q3 2026, buying an estimated $138K and bringing the position to 22,224 shares worth $790K. The position accounts for ﹤0.01% of the portfolio, ranked #1974.
Vanguard Asset Management first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.
- Vanguard Asset Management held 22,224 shares of Castle Biosciences worth $790K as of Q3 2026.
- Vanguard Asset Management bought 4,571 Castle Biosciences shares in Q3 2026, an estimated $138K.
- Castle Biosciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1974 holding.
- Vanguard Asset Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
- 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.